11.09.2018 • NewsDede WillamsNHSNICE

UK Health Minister slams Pharma Industry

UK Health Minister slams Pharma Industry (c) Africa Studio/Shutterstock
UK Health Minister slams Pharma Industry (c) Africa Studio/Shutterstock

British Health Minister Matt Hancock, in an interview with the London-based Times newspaper, has slammed the international pharmaceutical industry for trying to "rip off” UK taxpayers.

Using language the newspaper described as “unusually tough” for a health minister, it said Hancock accused drugmakers of "profiteering" on drugs developed with the help of government-funded research or National Health Service (NHS) patient data. The minister told the Times he would not allow Vertex to “hold the NHS to ransom."

Triggering for Hancock’s comments was an ongoing dispute between Boston, Massachusetts-based Vertex Pharmaceuticals and the NHS over pricing of a cystic fibrosis drug, along with divergent views between the heathcare system and drugmakers generally. 

In the minister’s view, the British healthcare system’s latest pricing offer for Vertex’s CF drugs was “incredibly generous,” and “Vertex needs to “accept the deal and supply the drug right now.”

Vertex and the UK government had sparred over pricing earlier, with the Boston drugmaker’s CEO Jeffrey Leiden complaining to Prime Minister Theresa May that rejection of the company’s recommended price by the industry watchdog National Institute for Health and Clinical Excellence (NICE) “threatens the entire UK biopharma ecosystem.”

Leiden suggested that NICE needs to revamp its assessment processes to keep up with “new science.” The agency, he charged, has shown "no flexibility" in negotiations and is adhering to "arbitrary value thresholds." This means that it is "placing a lower value on the life of a CF patient" in the UK, compared with other countries. The disease affects more than 10,000 people, according to the Cystic Fibrosis Trust.

The UK’s healthcare system rejects “a significant number of drugs” after an initial review, UK trade journal Fierce Pharma notes. After further negotiations, however, it said drugmakers do enjoy a certain degree of success in winning recommendations for coverage.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.